(1R,3R)-1-(2-fluoro-4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)phenyl)-3-methyl-2-(methylsulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole

ID: ALA4877968

Chembl Id: CHEMBL4877968

PubChem CID: 121411075

Max Phase: Preclinical

Molecular Formula: C25H29F2N3O3S

Molecular Weight: 489.59

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1Cc2c([nH]c3ccccc23)[C@@H](c2ccc(OCCN3CC(CF)C3)cc2F)N1S(C)(=O)=O

Standard InChI:  InChI=1S/C25H29F2N3O3S/c1-16-11-21-19-5-3-4-6-23(19)28-24(21)25(30(16)34(2,31)32)20-8-7-18(12-22(20)27)33-10-9-29-14-17(13-26)15-29/h3-8,12,16-17,25,28H,9-11,13-15H2,1-2H3/t16-,25-/m1/s1

Standard InChI Key:  DLVPQVIQBVJNHS-PUAOIOHZSA-N

Alternative Forms

  1. Parent:

    ALA4877968

    ---

Associated Targets(Human)

ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 489.59Molecular Weight (Monoisotopic): 489.1898AlogP: 3.88#Rotatable Bonds: 7
Polar Surface Area: 65.64Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.63CX LogP: 2.98CX LogD: 2.55
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.55Np Likeness Score: -0.73

References

1. Zbieg JR, Liang J, Li J, Blake RA, Chang J, Friedman L, Goodacre S, Hartman SJ, Rei Ingalla E, Kiefer JR, Kleinheinz T, Labadie S, Lai T, Liao J, McLean N, Metcalfe C, Mody V, Nannini M, Ortwine DF, Ran Y, Ray N, Roussel F, Sambrone A, Sampath D, Vinogradova M, Wai J, Wang T, Yeap K, Zhang B, Zheng X, Zhong Y, Wang X..  (2021)  Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer.,  50  [PMID:34425201] [10.1016/j.bmcl.2021.128335]

Source